{
    "nctId": "NCT01439945",
    "briefTitle": "Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer",
    "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cancer Survivor, Hot Flashes",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 289,
    "primaryOutcomeMeasure": "The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Women with a history of breast cancer (currently without malignant disease)\n* Bothersome hot flashes (defined by their occurrence \u2265 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)\n* Presence of hot flashes for \u2265 30 days prior to study registration\n* Willingness to provide the biologic specimens as required by the protocol\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Women who are postmenopausal as defined by absence of a period in the past 12 months or bilateral oophorectomy\n\n  * Women with at least one ovary but without a uterus should be deemed postmenopausal by either age over 55 or a combination of estrogen within a postmenopausal range (per local lab) and FSH over 40 mIU/mL\n  * No women of childbearing potential or who are premenopausal\n* Creatinine clearance \\> 30 mL/min\n* Ability to complete questionnaire(s) by themselves or with assistance\n* ECOG performance status 0 or 1\n* No history of allergic or other adverse reaction to magnesium\n* No diabetes\n* No patients with conditions that are implicated in decreased absorption of magnesium (e.g., Crohn disease, ETOH abuse)\n* No patients who have diarrhea where magnesium might make it worse (per provider discretion)\n\nPRIOR CONCURRENT THERAPY:\n\n* None of the following current (\u2264 28 days prior to registration) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but the patient must have been on a constant dose for \u2265 28 days and must not be expected to stop the medication during the study period):\n\n  * Antineoplastic chemotherapy (trastuzumab or lapatinib are allowed)\n  * Androgens\n  * Estrogens (any delivery route)\n  * Progestational agents\n* No prior use of magnesium for hot flashes\n* No current or planned use of gabapentin (for any reasons) or antidepressants (for any reasons) or other agents for treating hot flashes (except stable dose of vitamin E is allowed as long as it was started \\> 30 days prior to study registration and are to be continued through the study period; soy is allowed, if it is planned to be continued at the same dose during the study period)\n* No current use of magnesium for any indication (except one standard multiple vitamin dose is allowed per day)\n* Not taking diuretics, corticosteroids, bile acid sequestrants, and other prescription and over-the-counter medications that may affect magnesium levels\n* No current (\u2264 7 days prior to registration) or planned use of other non-drug therapies for managing hot flashes, such as acupuncture or yoga (use of these therapies for other reasons is allowed)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}